{{Refimprove|date=December 2008}}
{{Drugbox
| verifiedrevid = 461102248
| IUPAC_name = 9-fluoro-11,17-dihydroxy-10,13,17-trimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[''a'']phenanthren-3-one
| image = Fluoxymesterone.svg

<!--Clinical data-->
| tradename =  
| Drugs.com = {{drugs.com|monograph|fluoxymesterone}}
| MedlinePlus = a682690
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = X
| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
| legal_UK = <!-- GSL / P / POM / CD -->
| legal_US = <!-- OTC / Rx-only -->
| legal_status = Schedule III Controlled Substance
| routes_of_administration =  

<!--Pharmacokinetic data-->
| bioavailability = 100% Oral
| protein_bound =  
| metabolism = Hepatic
| elimination_half-life = 9.5 hours
| excretion = urine

<!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}}
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 76-43-7
| ATC_prefix = G03
| ATC_suffix = BA01
| ATC_supplemental =  
| PubChem = 6446
| IUPHAR_ligand = 2861
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
 | DrugBank = DB01185
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 6205
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 9JU12S4YFY
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D00327
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 5120
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1445

<!--Chemical data-->
| C=20 | H=29 | F=1 | O=3 
| molecular_weight = 336.441 g/mol
| smiles = O=C4\C=C3/[C@]([C@@]2(F)[C@@H](O)C[C@]1([C@@H](CC[C@@]1(O)C)[C@@H]2CC3)C)(C)CC4
| InChI = 1/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
| InChIKey = YLRFCQOZQXIBAB-RBZZARIABG
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C20H29FO3/c1-17-8-6-13(22)10-12(17)4-5-15-14-7-9-19(3,24)18(14,2)11-16(23)20(15,17)21/h10,14-16,23-24H,4-9,11H2,1-3H3/t14-,15-,16-,17-,18-,19-,20-/m0/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = YLRFCQOZQXIBAB-RBZZARIASA-N
}}

'''Fluoxymesterone''' (trade name '''Halotestin''') is an [[anabolic steroid]] with strong [[androgenic]] properties that has been used in the treatment of male [[hypogonadism]], delayed [[puberty]] in males, and in the treatment of breast [[neoplasm]]s in women. It is approximately 5 times as potent as [[methyltestosterone]].{{Citation needed|date=January 2010}} The [[antitumor]] activity of fluoxymesterone appears related to reduction or competitive inhibition of prolactin receptors or estrogen receptors or production.{{Citation needed|date=January 2010}}

Like many C-17 alpha alkylated steroids, fluoxymesterone has poor binding to the [[androgen receptor]]. Even so, its actions are mediated by the androgen receptor, most-likely due to its prolonged plasma half-life.<ref>Seth Roberts (2009). ''Anabolic Pharmacology'' .</ref>

It is considered a very toxic oral drug.

Though the half-life of fluoxymesterone is about 9.2 hours.{{Citation needed|date=January 2010}}

==Synthesis==

Fluoxymesterone can be prepared from 11Î±-hydroxy-17-methyltestosterone:<ref>{{Cite journal | author = Herr, M. E.; Hogg, J. A.; Levin, R. H. | journal = J. Amer. Chem. Soc. | year = 1956 | volume = 78 | pages = 501 | doi = 10.1021/ja01583a073 | issue = 2}}</ref>
:[[File:Fluoxymesterone.png|500px]]

==References==
{{reflist}}

==Further reading==

* {{cite book
  | last = Daniels 
  | first =  R. C.
  | authorlink =  
  | coauthors =  
  | title = The Anabolic Steroid Handbook
  | publisher = Richard C Daniels 
  | date = February 1, 2003
  | location = 
  | url= http://www.amazon.com/Anabolic-Steroid-Handbook-R-Daniels/
  | doi = 
  | isbn = 0-9548227-0-6
  | page = 80 }}


{{Anabolic steroids}}
{{Androgenics}}

[[Category:Androgens]]
[[Category:Anabolic steroids]]
[[Category:Organofluorides]]
[[Category:Alcohols]]
[[Category:Ketones]]